Genetic aspects of the hemostatic system in cerebrovascular disease

Neurology

Volumn 57, Issue 5 SUPPL. 2, 2001, Pages

  Catto, A J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; GENETIC DISORDER; HEMOSTASIS; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 0035845660     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.57.suppl_2.s24     Document Type: Article

References (82)

1. Infarcts of undetermined cause: The NINCDS stroke data bank
2. A study of twins and stroke
3. Importance of cerebrovascular disease in studies of myocardial infarction
4. Concordance for mortality with special reference to ischaemic heart disease and cerebrovascular disease
5. The genetics of haemostasis: A twin study
6. Similarities of genetic (spontaneous) hypertension: Man and rat
7. Cerebral infarction after middle cerebral artery occlusion in progenies of spontaneously stroke-prone and normal rats
8. Familial aggregation of stroke. The Framingham Study
9. Analysis of risk factors for stroke in a cohort of men born in 1913
10. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12
11. Clinical spectrum of CADASIL: A study of 7 families
12. A study of haemostasis in ischaemic cerebro vascular disease. I. Abnormalities in factor VIII and anti-thrombin
13. Hypercoagulability in acute stroke: Prognostic significance
14. The serial haemostasis related changes in patients with cerebral infarction: Comparison between progressing and non-progressing stroke
15. Evaluation of some coagulation parameters in cerebral ischaemia
16. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke
17. 2 antiplasmin
18. Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism
19. Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease
20. Clinical significance of new coagulation and fibrinolytic markers in ischemic stroke patients
21. Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in stroke
22. Altered coagulation in cerebral ischaemia. Platelet, thrombin and plasmin activity
23. Coagulation inhibitor levels in pneumonia and stroke: Changes due to consumption and acute phase reaction
24. In vitro diagnosis of fibrinolysis: Present status and desired improvements
25. Genetic factors determining thrombosis and fibrinolysis
26. Linkage between inherited resistance to activated protein C resistance and factor V mutation in venous thrombosis
27. Mutation in blood coagulation factor V associated with resistance to activated protein C
28. World distribution of factor V Leiden mutation
29. Special report on mutation in the gene coding for coagulation factor V
30. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke
31. Factor V Leiden mutation and completed stroke
32. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
33. Cerebral venous sinus thrombosis associated with factor V gene mutation
34. Prothrombin gene G20210→A transition is a risk factor for cerebral venous thrombosis
35. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
36. Fibrinogen as a risk factor for stroke and myocardial infarction
37. Fibrinogen and risk of cardiovascular disease
38. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes
39. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study
40. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease
41. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations
42. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study
43. Genetic and cultural inheritance of plasma fibrinogen concentration
44. Beta-fibrinogen gene polymorphism (C148→T) is associated with carotid artherosclerosis: Results of the Austrian Stroke Prevention Study
45. Gender-specific associations of the fibrinogen B beta 448 polymorphism, fibrinogen levels, and acute cerebrovascular disease
46. Genetic variation in the promoter region of the beta-fibrinogen gene is associated with ischemic stroke in a Japanese population
47. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplifcation: Identification of polymorphisms at positions A alpha 312 and B beta 448
48. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function
49. Alpha-chain domain of fibrinogen controls generation of fibrinoligase (coagulation factor XIIIa). Calcium ion regulatory aspects
50. Association of the alpha-fibrinogen Thr312Ala polymorphism with post-stroke mortality in subjects with atrial fibrillation
51. Factor VII activity and ischaemic heart disease: Fatal and non-fatal events
52. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
53. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals
54. Polymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and post-stroke mortality
55. The physiology and biochemistry of factor XIII
56. Association of a common polymorphism in the factor XIII gene with myocardial infarction
57. Clustering of haemostatic risk factors with FXIIIVal34Leu in patients with myocardial infarction
58. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males
59. Association of a common polymorphism in the factor XIII gene with venous thrombosis
60. Factor XIII Val34Leu is a genetic risk factor involved in the aetiology of venous thrombosis
61. Factor XIII Val 34 Leu: A novel association with primary intracerebral hemorrhage
62. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction
63. Effect of the FXIII Val34Leu polymorphism on the interaction between platelets and cross-linked fibrin
64. The relationship between polymorphisms of the fibrinogen and FXIII genes, fibrinogen levels and fibrin structure
65. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerisation and fibrin clot formation
66. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure
67. Fibrin gel network characteristics and coronary heart disease: Relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis
68. Proneness to the formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age
69. Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease
70. The effect of fibrin structure on fibrinolysis
71. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction
72. Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage
73. The natural inhibitors of fibrinolysis
74. Fibrinolytic activity and coronary artery disease
75. Haemostatic function in myocardial infarction
76. Haemostatic function and cardiovascular death: Early results of a prospective study
77. Plasminogen activator inhibitor in acute stroke
78. Decreased fibrinolytic stimulation by a short-term venous occlusion test in patients with cerebrovascular disease
79. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in Hep G2 cells
80. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease
81. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women